Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma

To date, there is no standard third-line therapy for EGFR- and ALK-negative lung squamous cell carcinoma (SCC). Apatinib, an oral small-molecule VEGFR-2 inhibitor, has shown good therapeutic effect and safety in chemotherapy-refractory gastric cancer, but its efficacy in lung SCC is not determined....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaofen, Li, Xia, Fang, Xuefeng, Yuan, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052933/
https://www.ncbi.nlm.nih.gov/pubmed/30038504
http://dx.doi.org/10.2147/OTT.S154567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052933/
https://www.ncbi.nlm.nih.gov/pubmed/30038504
http://dx.doi.org/10.2147/OTT.S154567

Ejemplares similares